Polyol-IFN-&bgr;conjugates modified at Cys-17 and composition containing same
US6638500B1 · kind B1 · utility
38Cited by
8References
5Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Oct 30, 2000 |
| Grant date | Oct 28, 2003 |
| Priority date | — |
| Expiry date | Dec 31, 2020 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P39/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
PEG-IFN-&bgr; conjugates, where a PEG moiety is covalently bound to Cys17 of human IFN-&bgr;, are produced by a process of site specific PEGylation with a thiol reactive PEGylating agent. A pharmaceutical composition and a method for treating infections, tumors and autoimmune and inflammatory diseases are also provided. The invention further relates to a method for the stepwise attachment of PEG moieties in series to a polypeptide, and more particularly to IFN-&bgr;.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.